IP Library Granted Patent US 10,731,157
Granted Patent B2
US 10,731,157 · App. 15/904,224 · Granted Aug 4, 2020

Polynucleotide nanoparticles for the modulation of gene expression and uses thereof

Inventor: Todd M. Hauser (Seattle, WA)
Assignee: HALO-BIO RNAI THERAPEUTICS, INC.
C12N15/113A61K9/14A61P35/00C12N15/111C12N15/82C12N2310/14C12N2310/16C12N2310/351C12N2310/51C12N2310/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,731,157
App. No.
15/904,224
Granted
Aug 4, 2020
Kind
B2
Abstract

The present invention is directed to novel self-forming polynucleotide nanoparticles, and the use of such nanoparticles and compositions comprising the same for gene modulation in a variety of organisms.

Claims (22)

1. An isolated polynucleotide nanoparticle comprising a contiguous polynucleotide comprising two or more MV-RNA sequences, each MV-RNA sequence joined by at least one linkage nucleotide,

wherein the contiguous polynucleotide is self-forming into the nanoparticle having a diameter of approximately 40-100 nm with approximately twice the ratio of stems near the surface of the nanoparticle than at the core of the nanoparticle.

2. An isolated polynucleotide nanoparticle approximately 100 nm diameter with at least four times the ratio of stems on the outer surface than at the center, comprising stacked sets of three MV-RNA, wherein each stacked MV-RNA set is separated by a linking element.

3. The isolated polynucleotide nanoparticle of claim 1 , wherein the polynucleotide nanoparticle comprises aptamer or cellular uptake sequences on one or more surface loops.

4. The isolated polynucleotide nanoparticle of claim 1 , wherein the polynucleotide nanoparticle has a general structure set forth in any one of FIG. 1 (2 nd to 5 th graphics counting from left to right), FIG. 2 (2 nd to 6 th graphics counting from left to right), and FIG. 3 .

5. The isolated polynucleotide nanoparticle of claim 1 , wherein (i) the 5′ end of the contiguous polynucleotide hybridizes to a reverse complement sequence of the 3′ end of the contiguous polynucleotide to form a stem or (ii) the first MV-RNA in the nanoparticle comprises both the 5′ end and the 3′ end of the contiguous polynucleotide to close the nanoparticle.

6. The isolated polynucleotide nanoparticle of claim 1 , wherein the at least one linkage nucleotide comprises: (i) a stem-loop structure or (ii) dinucleotide or (iii) mononucleotide.

7. The isolated polynucleotide nanoparticle of claim 1 , wherein the polynucleotide nanoparticle comprises natural or synthetic RNA or DNA.

8. The isolated polynucleotide nanoparticle of claim 1 , wherein the at least one linkage nucleotide is 1-12 nucleotides.

9. The isolated polynucleotide nanoparticle of claim 1 , wherein the polynucleotide nanoparticle is without a 5′ phosphate end or 3′ hydroxyl terminus.

10. The isolated polynucleotide nanoparticle of claim 1 , wherein the polynucleotide nanoparticle is expressed within a host cell selected from a plant cell or human cell or yeast cell or bacterial cell, or in vitro transcription.

11. The isolated polynucleotide nanoparticle of claim 1 , wherein the polynucleotide nanoparticle is expressed within a host cell and targets genes other than the host.

12. A composition comprising the isolated polynucleotide nanoparticle of claim 1 , in combination with a physiologically acceptable excipient.

13. The isolated polynucleotide nanoparticle of claim 2 , wherein the polynucleotide nanoparticle contains aptamer or cellular uptake sequences on one or more surface loops.

14. The isolated polynucleotide nanoparticle of claim 2 , wherein the linkage element comprises: (i) a stem-loop structure or (ii) dinucleotide or (iii) mononucleotide cleavable by an endonuclease.

15. The isolated polynucleotide nanoparticle of claim 2 , wherein the polynucleotide nanoparticle comprises natural or synthetic RNA or DNA.

16. The isolated polynucleotide nanoparticle of claim 2 , wherein the linkage element sequence is 3-12 nucleotides.

17. The isolated polynucleotide nanoparticle of claim 2 , wherein the polynucleotide nanoparticle is a single polynucleotide nanoparticle circularized with ribozyme cleavage.

18. The isolated polynucleotide nanoparticle of claim 2 , wherein the polynucleotide nanoparticle is expressed within a host cell selected from a plant cell or human cell or yeast cell or bacterial cell, or in vitro transcription.

19. The isolated polynucleotide nanoparticle of claim 2 , wherein the polynucleotide nanoparticle is expressed within a host cell and targets genes other than the host.

20. A composition comprising the isolated polynucleotide nanoparticle of claim 2 , in combination with a physiologically acceptable excipient.

21. The isolated polynucleotide nanoparticle of claim 2 , wherein the polynucleotide is single-stranded and the nanoparticle is self-forming.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2020
From: HAUSER, TODD M
To: HALO-BIO RNAI THERAPEUTICS, INC.
Reel/Frame 053370/0058 →
Continuity (3)
Continuation PCTUS2016048492 · Aug 24, 2016
Provisional Application 62209278 · Aug 24, 2015
Related Publication 20190055555A1 · Feb 21, 2019